Proposal to list interventional radiology products supplied by Bard Australia

Hospital devices Consultation Closed

What we’re proposing

PHARMAC is seeking feedback on a proposal to list a range of interventional radiology products in Part III of Section H of the Pharmaceutical Schedule from 1 December 2018 through a provisional agreement with Bard Australia Pty Limited ("Bard").

Consultation closes at 5pm on Wednesday 17 October 2018 and feedback can be emailed to

What would the effect be?

From 1 December 2018, Bard’s range of Interventional Radiology Products would be listed under the proposed national agreement for all DHBs to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).

The proposed Agreement would provide consistent terms and conditions for these devices for all DHB purchases from the proposed date of listing on the Pharmaceutical Schedule and would supersede any existing DHB contracts with Bard for the proposed products.

Based on current usage, the proposed Agreement would be cost neutral for DHBs.

DHBs would be able to continue to purchase other suppliers’ ranges of Interventional Radiology Products, as the Agreement would not be for sole supply.

DHBs would have access to educational services which would be tailored to suit the needs of the individual DHBs.

Who we think will be interested

  • Suppliers and Wholesalers
  • DHB Staff
    • Procurement and supply chain personnel
    • Interventional radiology staff
    • Theatre staff
    • Perioperative staff

About interventional radiology products

Interventional radiology refers to a range of minimally invasive alternatives to surgery to diagnose and treat a variety of conditions, that are performed using radiologic imaging guidance to precisely target the intervention. The procedures are performed using catheters inserted via either radial or femoral arteries or veins.

The imaging modalities used include general radiography including fluoroscopy, angiography, ultrasound, computed tomography, and magnetic resonance imaging.

Interventional radiology in some form is performed in all hospitals across New Zealand.

Why we’re proposing this listing

In September 2017, PHARMAC issued a Request for Proposals (RFP) for interventional radiology products.

The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.

PHARMAC has been working with suppliers to seek provisional agreements and this is the latest proposal to arise from that process. We intend to consult on proposed agreements with other suppliers over the next few months.

Details about our proposal

PHARMAC has entered into a provisional agreement with Bard for a range of Interventional Radiology Products that would result in listing 1096 products on the Pharmaceutical Schedule from 1 December 2018.

A full list of the products has not been included in this consultation for brevity, however we are making it available along with pricing information to appropriate DHB personnel.

DHBs would be able to continue to choose which Interventional Radiology Products they purchase.

The table on the following page information provides a summary of the brands and product ranges in the proposed agreements:



Bard Peripheral Vascular

  • Rival
  • Ultraverse
  • ReKross
  • Conquest
  • Atlas
  • Dorado
  • VascuTrak
  • Navarre
  • Fluency
  • E-Luminexx
  • Lifestent
  • Venovo
  • Lifestream
  • Valeo
  • Denali
  • Bard
  • Microtek
  • Namic
  • Lifemed

To provide feedback

Send us an email: by 5pm on Wednesday 17 October 2018.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.